Joshua T. Brumm - Feb 29, 2024 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role
CEO & President, Director
Signature
/s/ Richard Scalzo, Attorney-in-Fact
Stock symbol
DYN
Transactions as of
Feb 29, 2024
Transactions value $
-$2,341,519
Form type
4
Date filed
3/1/2024, 09:38 PM
Previous filing
Jan 31, 2024
Next filing
Mar 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DYN Common Stock Options Exercise $30.6K +5.52K +0.98% $5.54 569K Feb 29, 2024 Direct F1
transaction DYN Common Stock Sale -$152K -5.52K -0.97% $27.50 563K Feb 29, 2024 Direct F1, F2, F3
transaction DYN Common Stock Options Exercise $523K +94.5K +16.77% $5.54 658K Mar 1, 2024 Direct F1
transaction DYN Common Stock Sale -$536K -19K -2.88% $28.25 639K Mar 1, 2024 Direct F1, F2, F4
transaction DYN Common Stock Sale -$2.17M -74.1K -11.6% $29.23 565K Mar 1, 2024 Direct F1, F2, F5
transaction DYN Common Stock Sale -$42K -1.41K -0.25% $29.70 563K Mar 1, 2024 Direct F1, F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DYN Stock option (right to buy) Options Exercise $0 -5.52K -5.12% $0.00 102K Feb 29, 2024 Common Stock 5.52K $5.54 Direct F7
transaction DYN Stock option (right to buy) Options Exercise $0 -57.8K -56.52% $0.00 44.5K Mar 1, 2024 Common Stock 57.8K $5.54 Direct F7
transaction DYN Stock option (right to buy) Options Exercise $0 -36.6K -9.66% $0.00 343K Mar 1, 2024 Common Stock 36.6K $5.54 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 530,300 unvested RSUs.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.56 to $29.56, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.58 to $29.88, inclusive.
F7 The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024.